ILinagliptin

Igama leMchiza:

8-[(3R)-3-aminopiperidin-1-yl]-7-(kodwa-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3 , 7-dihydro-1H-purine-2,6-dione

Ikhowudi yoncumo:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Ikhowudi ye-InChi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

Isitshixo se-InChi:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Igama elingundoqo:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Ukunyibilika:Inyibilika kwi-DMSO

Ugcino:0 - 4°C ixesha elifutshane (iintsuku ukuya kwiiveki), okanye -20°C ixesha elide (iinyanga).

Inkcazo:

I-Linagliptin, ekwabizwa ngokuba yi-BI-1356, yi-DPP-4 inhibitor ephuhliswe ngu-Boehringer Ingelheim kunyango lwe-type II yeswekile. I-Linagliptin (kanye ngemini) yamkelwa yi-US FDA nge-2 kaMeyi ka-2011 kunyango lwe-type II yeswekile. Ithengiswa nguBoehringer Ingelheim kunye noLilly.

Ithagethi: DPP-4